Dexmedetomidine as an Adjuvant to Ropivacaine in Ultrasound Guided Paediatric Caudal Epidural Block: A Randomised Controlled Study

Anaesthesia Section

B SARVESH<sup>1</sup>, PRASHANTH G RAJ<sup>2</sup>, MS SOUMYA<sup>3</sup>, VASANTHA KUMAR<sup>4</sup>, KANCHAN SHARMA<sup>5</sup>, AMIT AGARWAL<sup>6</sup>

# ABSTRACT

**Introduction:** Caudal epidural block is a reliable technique to provide perioperative analgesia for infra-umbilical surgeries in paediatric population. Several adjuvants are used along with local anaesthetics to prolong the postoperative anaesthesia.

**Aim:** To evaluate the efficacy of Dexmedetomidine as an adjuvant to ropivacaine in prolonging the duration of postoperative analgesia and reduction of pain scores in paediatric patients undergoing infra-umbilical surgeries.

**Materials and Methods:** This was a double-blinded randomised study, conducted at a tertiary care institution. Sixty patients (2-12 years) of ASA physical status classes 1 and 2 were randomly allocated into two groups. After general anaesthesia, each patient received an ultrasound-guided caudal block. Group R (n=30) received 0.25% ropivacaine (1 mL/kg) +0.5 mL saline and Group RD (n=30) received 0.25% ropivacaine 1 mL/kg +1  $\mu$ g/kg dexmedetomidine (in 0.5 mL volume). Duration of

postoperative analgesia, FLACC pain scores, consumption of rescue analgesics, sedation and adverse-effects were assessed during the 24-hours. The present authors used Student's t-test and chi-square test for statistical analysis.

**Results:** The duration of postoperative analgesia was significantly prolonged in Group RD,  $790.77\pm7.70$  minutes as compared to Group R,  $377.97\pm12.20$  minutes (p-value <0.001). Group RD achieved lower FLACC pain scores compared to group R. There were no significant differences in the incidence of adverse-effects.

**Conclusion:** Dexmedetomidine (1  $\mu$ g/kg) as an adjuvant to ropivacaine 0.25% (1 mL/kg) in an ultrasound-guided caudal block significantly prolongs the duration of postoperative analgesia and reduces FLACC pain score in paediatric patients undergoing infra-umbilical surgeries without any significant adverse-effects.

Keywords: Infra-umbilical surgeries, Postoperative analgesia, Sacral hiatus

# INTRODUCTION

Caudal block is a reliable and safe technique in paediatric patients. It reduces the anaesthetic agent requirement, attenuates surgical stress and provides better postoperative analgesia.

The drawback of caudal block is the short duration of action after a single injection [1]. Ultrasonography-guided caudal block has gained popularity because of its lower complication rates [2,3]. Variety of adjuvants, such as epinephrine, opioid, and  $\alpha_2$  agonists have been used to prolong the duration of caudal analgesia [4,5].

Dexmedetomidine is a stereoisomer of medetomidine and a highly selective  $\alpha_2$ -adrenergic receptor agonist with eight times more specificity as compared to clonidine [6]. Dexmedetomidine is conferred with anxiolytic, sedative, sympatholytic and analgesic properties without significant respiratory depressant effect [7].


The present authors hypothesised that dexmedetomidine in a dose of 1  $\mu$ g/kg, as an adjuvant to ropivacaine 0.25% (1 mL/kg) in caudal block would provide prolonged postoperative analgesia and reduced pain scores with minimal adverse effects in paediatric patients.

This randomised, double-blinded, placebo-controlled study was designed to compare the analgesic effect of caudal ropivacaine with dexmedetomidine versus ropivacaine in paediatric patients undergoing infra-umbilical surgeries.

# MATERIALS AND METHODS

This was a double-blinded randomised study, conducted at a tertiary care institution. This study was conducted after getting clearance

from the Institutional Ethical Committee (AIMS/IEC/2180/2017-2018) and obtaining written informed consent from guardians of patients. The study was conducted from January 2018 to December 2018. Sixty patients, belonging to the American Society of Anaesthesiologist (ASA) Classes 1 and 2, in the age group of 2-12 years, of either gender, who underwent infra-umbilical surgery, were enrolled [Table/Fig-1].



Patients with history of developmental delay, mental retardation and known allergy to study drugs, injection site infection, neurological disease, coagulopathies, spinal deformities and parental refusal were excluded from the study.

Patient's age, weight, and baseline vital parameters were recorded, detailed history and examinations were done at pre anaesthestic visit. All patients were kept nil per orally as per standard protocol (2 hours for clear liquid and 6 hours for semisolid and solid food).

Randomisation was done with a computer-generated list and children were equally assigned into two groups R (ropivacaine) and RD (ropivacaine plus dexmedetomidine), with 30 members in each group. An anaesthesiologist not involved in the study prepared the study of drugs.

Upon arrival of patient in the operation theatre, ASA standard monitor was connected and baseline parameters such as Heart Rate (HR), Blood Pressure (BP), Oxygen Saturation (SpO<sub>2</sub>), and Respiratory Rate (RR) were recorded. Patients were induced with 8% sevoflurane in oxygen with spontaneous ventilation, IV line was secured with either 22 or 24 gauge cannula, fluid was infused as calculated and an appropriate sized Laryngeal Mask Airway (LMA) was inserted. After the LMA was inserted, sevoflurane concentration was reduced to 2%; patients were placed in left lateral position and with aseptic precautions, ultrasound-guided caudal block was administered under realtime guidance with a high frequency (5-10 MHz) ultrasound probe (Micromaxx<sup>™</sup> Sonosite, Inc., Bothell, WA98021, USA). An axial image for the sacral hiatus and dorsal sacrococcygeal ligament between the two sacral cornua were obtained and then transducer was rotated by around 90° to obtain the sagittal view of the sacral hiatus. With real-time guidance, a 23gauge, 5 cm needle was introduced and advanced at around 45° angulation until it pierced the dorsal sacrococcygeal ligament. After careful negative aspiration for blood and CSF, study drug was injected.

- Group R received 0.25% ropivacaine 1 mL/kg+0.5 mL normal saline.
- Group RD received 0.25% ropivacaine 1 mL/kg+1 µg/kg dexmedetomidine (in 0.5 mL volume).

After noting the injection time, patients were turned back to supine position. Anaesthesia was maintained using sevoflurane in oxygen/air (50:50) mixture. Intraoperatively, no other drugs like narcotics, analgesics, sedatives or anti-emetics were administered. After the surgery was completed, LMA was removed and the patients were transported to the Post Anaesthesia Care Unit.

The present authors assessed the onset of block by applying mechanical stimulus at surgical site after 5, 10 and 15 minutes of the injection. The successful onset of the block is defined as the time in minutes between injection of local anaesthetic and the absence of motor response or absence of >20% increase in HR on application of mechanical stimulation. Patients with patchy and failed caudal block were excluded from the study.

The present authors recorded vital parameters before induction, just before and after skin incision and every five minutes for half hour, and every 15 minutes for one hour. The present authors assessed the postoperative pain using the Face, Legs, Activity, Cry, Consolability (FLACC) pain scale. The present authors used Ramsay sedation scale to assess postoperative sedation. The duration of adequate caudal analgesia was recorded, and paracetamol syrup was administered as 10 mL/kg at FLACC pain score ≥4 and total dose of rescue analgesic administered in observation period was recorded.

Patients were monitored for adverse-effects such as nausea, vomiting, bradycardia, respiratory depression and hypotension and

treated accordingly. The present authors calculated the sample size to be 30 in each group to establish a significant difference in the mean duration of analgesia and total analgesic doses requirement during first 24 hours in both groups with a  $\alpha$  error of 0.05 [8].

# STATISTICAL ANALYSIS

The data obtained from the present study was tabulated and analysed using the computer software (SPSS for Windows, Version 16.0. Chicago, SPSS Inc.). The quantitative data were compared using Student's t-test. We used Mann-Whitney U-test for comparing skewed data. Qualitative or categorical data were expressed as frequencies and analysed with Chi-square or Fisher's exact test. The p-value<0.05 was accepted as statistically significant.


# RESULTS


Demographic profile of patients and operative characteristics between both groups were similar [Table/Fig-2]. There were no significant differences in the heart rate [Table/Fig-3] and mean arterial pressure [Table/Fig-4] between the two groups at any time interval (p-value >0.05)

Character	Group R (n=30)	Group RD (n=30)	p-value	
Age (years)	6.67±2.83	6.5±2.92	0.379	
Weight (kg)	22.6±3.89	22±4.59	0.294	
Sex (m/f)	28/2	29/1		
Duration of surgery(min)	53.40±9.53	53.09±12.26	0.458	
[Table/Fig-2]: Demographic profile of patients.				

Group R-Ropivacaine; Group RD-Ropivacaine+Dexmedetomidine, p-value >0.05; not significant,








The mean duration of analgesia was longer in Group RD (790.77±7.70 minutes) as compared to Group R (377.97±12.20 minutes), p-value<0.0001 [Table/Fig-5]. The total number of doses of rescue analgesic required were lesser in Group RD as compared to Group R, p-value <0.05 [Table/Fig-5]. Group R patients demonstrated significantly higher FLACC score compared to Group RD patients, where 22 out of 30 children achieved a FLACC score of 4 at 6<sup>th</sup> hour compared with 0 patients in Group RD, whereas 26 out of 30 children of Group RD had FLACC score of 4 at 16<sup>th</sup> hour of postoperative period [Table/Fig-6,7]. The incidence of sedation, nausea, vomiting and the use of antiemetic medications were not statistically significant in either group [Table/Fig-8].

# DISCUSSION


In the present study, the present authors administered dexmedetomidine 1  $\mu$ g/kg as an adjuvant to ropivacaine 0.25% (1 mL/kg) as a single shot caudal block and observed that the

Parameter	Group R n (30)	Group RD n (30)	p-value
Duration of Analgesia	377.97±12.20 min	790.77±7.70 min	<0.001*
Number of doses of rescue analgesic required	n (%)	n (%)	
1 dose	2 (6.67%)	27 (90%)	
2 dose	9 (30%)	3 (10%)	
3 dose	19 (63.33%)		

[Table/Fig-5]: Duration of analgesia and rescue analgesic doses required in 24 hours \*p-value<0.001; highly significant, Values expressed as Mean±SD and number (percentage); Group B-Bonivacaine: Group BD-Bonivacaine+Dexmedetomidine



h-Hour, y axis-number of patients



[Table/Fig-7]: FLACC score of group RD. h-hour, v axis- number of patients

Time	Group R	Group RD		
End of surgery	3 (2-3)	3 (2-3)		
1 hour	1 (0-2)	1 (0-2)		
2 hour	1 (0-2)	1 (0-2)		
3 hour	1 (0-2)	1 (0-2)		
4 hour	0 (0-0)	0 (0-0)		
<b>[Table/Fig-8]:</b> Ramsay sedation score during postoperative period. Group R-Ropivacaine; Group RD-Ropivacaine+Dexmedetomidine Values expressed as median (range)				

duration of postoperative analgesia (FLACC <4) without any rescue, analgesic was significantly longer in Group RD than Group R. In support of the present study, Jain K et al., also administered dexmedetomidine in a dose of 1  $\mu$ g/kg, as an adjuvant with 0.25% ropivacaine caudally, and concluded that the duration of postoperative analgesia was significantly longer in the group receiving ropivacaine-dexmedetomidine mixture than the group receiving ropivacaine alone [9].

Similarly, Anand VG et al., utilised dexmedetomidine and clonidine, in doses of 2 µg/kg, as adjuvant with 0.25% bupivacaine in caudal blocks [10]. They concluded that the duration of analgesia was significantly prolonged in the group receiving bupivacaine with dexmedetomidine or bupivacaine-clonidine mixture compared to the group receiving only bupivacaine. Neogi M et al., compared clonidine 1 µg/kg and dexmedetomidine 1 µg/kg as adjuvants to ropivacaine 0.25% in caudal block in paediatric patients and concluded that mean (SD) duration of analgesia was 15.26 hours in dexmedetomidine group, which was significantly prolonged as

compared to clonidine group 13.17 hours and ropivacaine group 6.32 H [11].

In the present study, we found that the mean time to first rescue analgesic demand was significantly prolonged and cumulative doses of rescue analgesic obtained during the observation period was significantly less in Group RD as compared to Group R. In support of the present study, Saadawy I et al., also found in their study that 77% of the children in the Bupivacaine-Dexmedetomidine (BD) group versus 10% in group bupivacaine did not require additional analgesia and cumulative postoperative analgesic requirements were significantly less in the BD group (p-value <0.01) during the first 24 hours postoperative period [12].

The pre, intra, and postoperative haemodynamic variables [Table/Fig-2,3] between the groups R and RD were comparable and were statistically insignificant and none of them required therapeutic interventions. There were no episodes of clinically significant postoperative complications such as postoperative nausea and vomiting, respiratory depression, urinary retention, pruritus, hypotension, and bradycardia in any of the groups. The results of the present study depicts that in addition to prolonged postoperative analgesia, dexmedetomidine has a favourable safety profile and stable haemodynamics, which are supported by the reports published by many other authors [13-16].

### LIMITATION

The present study lacked a group with IV dexmedetomidine. Hence, we could not comment on the potential local effect of dexmedetomidine. Therefore, there is a need of future studies with IV dexmedetomidine as a control group to evaluate potential local effects of dexmedetomidine.

# CONCLUSION

The present results allow us to conclude that addition of dexmedetomidine (1  $\mu$ g/kg) to caudal ropivacaine 0.25% at 1 mL/kg significantly prolonged postoperative analgesia in children undergoing infra-umbilical surgeries without notable side effects. Hence, dexmedetomidine may be used as a safe and effective adjuvant for caudal analgesia in paediatric patients.

### REFERENCES

- Lloyd-Thomas AR. Pain management in pediatric patients. Br J Aanesth 1990;64:85-104.
- [2] Polaner DM, Taenzer AH, Walker BJ, Bosenberg A, Krane EJ, Suresh S, et al. Pediatric Regional Anesthesia Network (PRAN): a multi-institutional study of the use and incidence of complications of pediatric regional anesthesia. Anesth Analg. 2012;115:1353-64.
- [3] Chen CP, Tang SF, Hsu TC, Tsai WC, Liu HP, Chen MJ, et al. Ultrasound guidance in caudal epidural needle placement. Anesthesiology. 2004;101:181-84.
- [4] de Beer DA, Thomas ML. Caudal additives in children-Solutions or problems? Br J Anesth 2003;90:487-98.
- [5] Vetter TR, Carvallo D, Johnson JL, Mazurek MS, Presson RG Jr. A comparison of single-dose caudal clonidine, morphine, or hydromorphone combined with ropivacaine in pediatric patients undergoing ureteral reimplantation. AnesthAnalg 2007;104:1356-63.
- [6] Kaur M, Singh PM. Current role of dexmedetomidine in clinical anesthesia and intensive care. Anesth Essays Res 2011;5:128-33.
- [7] Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000;90(3):699-705..
- [8] Kamal M, Mohammed S, Meena S, Singariya G, Kumar R, Chauhan DS. Efficacy of dexmedetomidine as an adjuvant to ropivacaine in pediatric caudal epidural block. Saudi J Anaesth 2016;10:384-89.
- [9] Jain K, Sethi SK, Yadav SL, Mathur V, Thada B, Garg D. Dexmedetomidine enhances the efficacy of 0.25% ropivacaine for postoperative analgesia in pediatric caudal epidurals. Anaesth Pain and Intensive Care. 2018;22(2):199-206.
- [10] Anand VG, Kannan M, Thavamani A, Bridgit MJ. Effects of dexmedetomidine added to caudal ropivacaine in pediatric lower abdominal surgeries. Indian J Anesth. 2011;55:340-46.
- [11] Neogi M, Bhattacharjee DP, Dawn S, Chatterjee N. A comparative study between clonidine and dexmedetomidine used as adjuncts to ropivacaine for caudal analgesia in pediatric patients. J Anaesthesiol Clin Pharmacol. 2010;26:149-53.

- [12] Saadawy I, Boker A, Elshahawy MA, Almazrooa A, Melibary S, Abdellatif AA, et al. Effect of dexmedetomidine on the characteristics of bupivacaine in a caudal block in pediatrics. Acta Anaesthesiol Scand. 2009;53:251-56.
- [13] Ramsay MA, Luterman DL. Dexmedetomidine as a total intravenous anesthetic agent. Anesthesiology. 2004;101:787-90.
- [14] Ibacache ME, Muñoz HR, Brandes V, Morales AL. Single-dose dexmedetomidine reduces agitation after sevofluraneanesthesia in children. Anesth Analg. 2004;98:60-63.
- [15] Petroz GC, Sikich N, James M, van Dyk H, Shafer SL, Schily M, et al. A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. Anesthesiology. 2006;105:1098-110.
- [16] Agarwal A, Mittal AA, Chand T, Gautam MK. Evaluation of efficacy of caudal dexmedetomidine with ropivacaine for postoperative analgesia in paediatric lower abdominal surgeries. Indian Journal of Applied Research. 2016;6(3):129-33.

#### PARTICULARS OF CONTRIBUTORS:

- 1. Assistant Professor, Department of Anesthesiology, Adichunchanagiri Institute of Medical Sciences, Mandya, Karnataka, India.
- 2. Assistant Professor, Department of Anesthesiology, Adichunchanagiri Institute of Medical Sciences, Mandya, Karnataka, India.
- 3. Resident, Department of Radiology, KMCH, Coimbatore, Karnataka, India.
- 4. Professor, Department of Anesthesiology, Adichunchanagiri Institute of Medical Sciences, Mandya, Karnataka, India.
- 5. Consultant Pain Physician, Department of Pain Management, Aadhya Pain Management Centre, Jaipur, Rajasthan, India.
- 6. Consultant Anesthesiologist, Department of Anesthesiology, Rukmani Birla Hospital, Jaipur, Rajasthan, India.

#### NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Prashanth G Raj

Number 90, Belaku, Vivekananada Block, Teachers Layout, Mysore, Karnataka, India. E-mail: drsarveshb83@gmail.com

FINANCIAL OR OTHER COMPETING INTERESTS: None.

Date of Submission: Apr 05, 2019 Date of Peer Review: Apr 26, 2019 Date of Acceptance: May 03, 2019 Date of Publishing: Jun 01, 2019